Sai Life Sciences , a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the reappointment of Krishnamraju Kanumuri as Managing Director and CEO for a five-year term, along with its financial results for the first quarter of fiscal year 2026.

Leadership Continuity

The Board of Directors of Sai Life Sciences approved the reappointment of Krishnamraju Kanumuri as Managing Director & CEO for a term of five years, effective from September 1, 2025, to August 31, 2030. This decision, made during the board meeting held on August 7, 2025, is subject to shareholder approval at the upcoming Annual General Meeting scheduled for September 11, 2025.

Kanumuri, who has been with the company since 2004, has played a pivotal role in transforming Sai Life Sciences from a domestic service provider into a globally respected CRDMO. Under his leadership, the company has achieved significant milestones, including:

• A 25% revenue CAGR from 2022 to 2025
• Expansion of global footprint with R&D centers in Boston and Manchester
• Successful completion of the company's IPO in December 2024

Q1 FY2026 Financial Highlights

Sai Life Sciences also reported robust financial results for the quarter ended June 30, 2025:

The company demonstrated strong year-over-year growth, with revenue from operations increasing by 77.50% compared to the same quarter in the previous fiscal year. Sai Life Sciences also returned to profitability, reporting a profit after tax of ₹604.55 million for the quarter.

Earnings Per Share

The earnings per share (EPS) for Q1 FY2026 stood at:

• Basic EPS: ₹2.90 (not annualized)
• Diluted EPS: ₹2.83 (not annualized)

This marks a significant improvement from the loss per share reported in Q1 FY2025.

Annual General Meeting

The company announced that its 26th Annual General Meeting will be held on Thursday, September 11, 2025, at 10:30 AM (IST) through Video Conferencing / Other Audio-Visual Means.

Sai Life Sciences continues to operate in a single segment of providing Contract Research, Development, and Manufacturing (CRDMO) services, catering to pharmaceutical and biotech innovators globally. The reappointment of Krishnamraju Kanumuri and the strong financial performance indicate the company's commitment to sustained growth and leadership in the CRDMO space.

Sai Life Sciences Limited , a leading Contract Research, Development and Manufacturing (CRDMO) company, has reported robust financial results for the first quarter, demonstrating significant growth across key metrics.

Financial Highlights

The company's consolidated revenue from operations surged to Rs. 4,964.19 crore in Q1, marking a substantial increase from Rs. 2,797.23 crore in the corresponding quarter of the previous year. This impressive growth of 77.47% underscores the company's strong market position and expanding client base.

Profit after tax (PAT) showed a remarkable turnaround, with the company reporting a consolidated PAT of Rs. 604.55 crore, compared to a loss of Rs. 134.98 crore in the same quarter last year. This significant improvement in profitability reflects the company's operational efficiency and successful execution of its business strategies.

On a standalone basis, Sai Life Sciences reported equally impressive results:

The company's earnings per share (EPS) also showed substantial improvement, with consolidated basic EPS rising to Rs. 2.90, up from a loss per share of Rs. 0.74 in the corresponding quarter of the previous year.

Operational Performance

The strong financial performance can be attributed to the company's focus on its core CRDMO segment. Sai Life Sciences has been successful in leveraging its expertise in contract research, development, and manufacturing services, catering to the growing demands of the pharmaceutical and biotechnology industries.

Leadership Continuity

In a move that signals confidence in the current leadership, the Board of Directors has approved the reappointment of Mr. Krishnamraju Kanumuri as Managing Director & CEO for another five-year term, effective from September 1, 2025. This reappointment is subject to shareholder approval at the upcoming Annual General Meeting (AGM).

Corporate Updates

The company has scheduled its 26th Annual General Meeting for September 11, 2025, which will be conducted via video conferencing, in line with modern corporate practices and considering potential ongoing health precautions.

Outlook

With a strong start to the fiscal year and strategic leadership continuity, Sai Life Sciences appears well-positioned to capitalize on the growing opportunities in the global CRDMO market. The company's ability to turn around its profitability and achieve significant revenue growth demonstrates its resilience and adaptability in a dynamic industry landscape.